prostate cancer; screening; psa; mri

This expert panel discussion at the Southwest Prostate Cancer Symposium explores how prostate cancer screening and diagnostic decisions are made in real clinical practice. The conversation begins by discussing historical prostate-specific antigen (PSA) thresholds and why PSA alone is...

* Dr. Carlsson asserts that prostate cancer screening is moving toward integrated, risk-adapted models, combining PSA, biomarkers, imaging, and AI to optimize outcomes for men globally. Dr. Sigrid Carlsson, MD, PhD, MPH, Head, Division of Clinical Epidemiology of Early Cancer Detection...

Sigrid Carlsson, MD, Ph.D., MPH, Assistant Attending Epidemiologist at Memorial Sloan Kettering Cancer Center (MSKCC), discusses the current state of prostate cancer screening, focusing on PSA screening, risk calculators, biomarkers, and MRI. While not a perfect tool, PSA screening reduces...